Delivery of recombinant adeno-associated virus (rAAV) vectors to the newborn liver is followed by a rapid loss of episomal vector copies because of hepatocyte proliferation. In selected hepatocytes, integration of rAAV genomes can lead to a sustained expression of the transgene. The safety of in vivo gene therapy with single-stranded AAV vectors has been questioned in a study reporting a high incidence of hepatocellular carcinoma, associated with provirus integration events in mice that receive an singlestranded AAV injection at birth. To investigate the tumour-initiating potential of the newly established self-complementary AAV (scAAV) vectors in the liver, groups of newborn rats received intravenous injection of a scAAV vector encoding the green fluorescent protein (GFP), or were injected with phosphate-buffered saline (PBS) or diethylnitrosamine (DEN), a well-known liver tumour initiator. The rats were fed on a diet containing 2-acetylaminofluorene, a potent liver tumour-promoting agent to accelerate the carcinogenic process. After 2 months, the animals were killed and their livers analysed. Preneoplastic nodules were identified by glutathion S-transferase-p (GSTp) staining, and GFP expression was detected by immunohistochemistry. Vector genome integration events were analysed. The numbers of GSTp-positive foci were comparable in the PBS and the scAAV-GFP groups and significantly higher in the DEN group. The proportion of GSTp-positive foci that also expressed GFP was low and in the range expected for random occurrence. No specific integration hot spots were detected by linear amplification-mediated-PCR in transduced liver. In conclusion, scAAV transduction of newborn rat liver does not trigger preneoplastic lesions suggesting an absence of liver tumourigenesis.
INTRODUCTION
Adeno-associated virus (AAV) is a small, non-pathogenic, nonenveloped, replication-defective virus containing a singlestranded DNA genome of approximately 5 kb. Recombinant AAV (rAAV) is among the most promising gene delivery vectors, widely used in gene therapy for its ability to transduce various tissues and cell types with a high efficiency and to maintain transgene expression in vivo in differentiated cells. It has been shown that, although rAAV remains predominantly in an episomal form, rAAV genome can integrate into the genome of the host cell. [1] [2] [3] [4] The majority of experimental data in adult mice have shown that the injection of rAAV is safe. In a large meta-analysis on livertargeted gene transfer experiments, adult mice injected with rAAV, mainly via the portal vein, did not show a higher risk of developing hepatocellular carcinoma (HCC) than control mice. 5 In another study by the same authors, two different rAAV, encoding either a marker or a therapeutic gene (LacZ or oct), were injected into adult B6C3F1 mice, known to develop spontaneous HCC. No evidence of rAAV-induced malignancy was found. 6 Questions about the safety of in vivo gene transfer with rAAV have been raised in a study reporting a high incidence of HCC in rAAV-treated b-glucuronidase-deficient newborn mice (MPSVII mice). 7 Any increased risk of developing HCC is not due to the mouse strain, because an increase in tumour formation can also be observed in the liver of wild-type mice receiving the same rAAV vector. In that study, an analysis of integration sites (ISs) revealed the presence of rAAV genome in four samples of tumour tissue and all the vector genomes were integrated into a 6-kb region of chromosome 12. 8 Delivery of rAAV vectors to the newborn rat liver results in a high transduction of hepatocytes followed by a rapid loss of episomal vectors as a consequence of the rapid proliferation of these hepatocytes. In a previous study, we showed that in this setting, sustained expression of the transgene in selected, clustered hepatocytes results from integration of recombinant vector genomes. 9 In the present work, a specific protocol was designed to reveal this potential tumourigenic risk of rAAV transduction of the liver (Figure 1 ). It has long been known that liver carcinogenesis is a multistep process. The initiation stage involves interactions of carcinogens with DNA that lead to the formation of DNA adducts. This is followed by the promotion stage, in which the cells proliferate and form preneoplastic foci. Glutathion S-transferase-p (GSTp) is a well-established marker of preneoplastic lesions in various types of cancer. 10 In the final phase, progression, the cells continue to proliferate leading to malignant lesions with chromosomal abnormalities.
The Solt-Farber protocol has long been used to decipher liver carcinogenesis in rats. Initiation is usually carried out by a single injection of diethylnitrosamine (DEN). The promotion stage is then induced by feeding animals a diet containing the promoting agent 1 2-acetylaminofluorene (2-AAF). A partial hepatectomy (or the natural growth of the liver if the protocol is performed in young animals) triggers the proliferation of selected initiated hepatocytes. 11 We have adapted the Solt-Farber protocol in order to test the genotoxic potential of rAAV injection in newborn rats, and to evaluate the associated tumour initiation (Figure 1a) . Newborn rats received a single intravenous injection of a self-complementary AAV (scAAV) 2/8 vector encoding the green fluorescent protein (GFP), to mimic the initiation stage, followed by an 8-week 2-AAF-containing diet. The animals were then killed and the extent of preneoplastic development in their liver was evaluated by immunohistochemical analysis of the preneoplastic marker GSTp.
RESULTS AND DISCUSSION
One-day-old Wistar rats were injected in the temporal vein with a dose of 5.10 12 vector genomes kg À 1 (vg kg
) of scAAV2/8 vector-encoding GFP under the control of the cytomegalovirus (CMV) promoter (Figure 1b) . Rats in the control group received phosphate-buffered saline (PBS). To monitor the transduction efficiency, female rats were killed 10 days, 6 weeks and 14 weeks after scAAV-GFP injection and their livers were analysed, using immunohistochemistry to detect transgene expression and quantitative PCR to quantify vector genomes. Figure 2a shows representative patterns of expression of GFP, which was widespread and occurred in single cells throughout the liver parenchyma at 10 days. From 6 weeks after rAAV injection, persistent GFP expression was detected in hepatocytes that gathered in small clusters. After quantification (Figure 2b ), 10 days after injection, 40.09% of hepatocytes expressed GFP. The percentage dropped to 0.52% at 6 weeks and remained stable thereafter (0.40% at 14 weeks). The number of rAAV genomes per haploid genome (vg per hg) varied: 1.22 vg per hg at day 10 after rAAV injection, 0.24 after 6 weeks and 0.39 after 14 weeks. A recent study of scAAV injection in 1-day-old mice with a similar dose (5.10 10 vg per mouse), showed maximum hepatocyte transduction 7 days after injection, rapidly decreasing to o1% of the hepatocytes 5 weeks after injection, the latest time point in that study. 12 Our results concord with these data and extend the study to 6 and 14 weeks. They show a persistent expression of the transgene in some hepatocytes, and suggest that these hepatocytes contain a high number of copies of the vector. This confirms our previous work in which we also showed that these clusters are likely to correspond to cells in which integration of the viral genome had occurred. 9 In order to reveal any potential tumour-initiating risk of rAAV integration, tumourigenesis was hastened and amplified through a treatment with a tumour-promoting agent, 2-AAF, already used in the classic Solt-Farber protocol. At 6 weeks of age, male rats that had received either the scAAV-GFP vector (n ¼ 10), or PBS (n ¼ 9), or DEN (n ¼ 9), were put on a diet containing the promoting agent 2-AAF for 8 weeks, and were then killed ( Figure 1b ). Using immunohistochemistry, the livers were processed to detect the expression of the preneoplastic marker GSTp. In the DEN group, GSTp-positive cells appeared in large foci ( Figure 3 ). Quantification revealed 255 ± 12 GSTp-positive foci cm À 2 in the livers of the DEN-treated animals. In the animals that received the scAAV-GFP vector, there was a mean number of 27±3 GSTp-positive clones, comparable to that of the negative control group injected with PBS (34 ± 8 clones cm À 2 ). These few GSTp-positive foci likely result from the slight initiating action of the 2-AAF diet by itself. 13 The surface of GSTp-positive staining in liver sections was quantified as outlined in the methods section. The surfaces measured in the scAAV-GFP group and in the group that received no tumour-initiating agent were comparable and were significantly lower than that measured in the DEN-injected ) at 6 weeks (n ¼ 9). *Female rats were killed at 10 days (n ¼ 4), 6 weeks (n ¼ 3) and 14 weeks (n ¼ 3) in order to monitor the transduction efficiency. All male rats started a 8-week long diet with 0.02% of 2-AAF at 6 weeks. The animals were killed at 14 weeks.
scAAV transduction of newborn rat liver V Gauttier et al group, which reached 64.1±1.1%. These results show that, in this stringent setting, injection of rAAV to newborn rat does not have a tumour-initiating risk, as measured by the number and surface of GSTp-positive clones present in the rat livers after a 2-AAF diet.
To further analyse the initiating potential of scAAV vectors, we reasoned that if rAAV genome integration presented a tumourinitiating risk, one could assume that there would be preferential co-expression of both the GFP transgene and the preneoplastic marker GSTp in hepatocyte clusters. To investigate this, immunohistochemical detection of GFP and of GSTp was performed on serial sections prepared from the livers of the rats injected with the rAAV-GFP vector (Figure 4) . Figure 4a shows examples of these serial stainings. After quantification, the mean number of GFP-positive clones in the rats was 2.33±0.36 cm À 2 ( Figure 4b ). Rare GSTp-positive clones were found among these GFP-positive clones. Indeed, no colocalization of the two markers could be found in 5 out of the 10 rats of the group despite extensive screening, which implies a complete dissociation between GFP expression and tumour initiation. For the five other rats, the mean number of double positive clones was 0.15 ± 0.03 clones cm scAAV transduction of newborn rat liver V Gauttier et al very rare event, suggesting that expression of the transgene in a preneoplastic clone is a random phenomenon.
Finally, the viral genome copy number was measured in whole liver samples from all the rats (Figure 4d ). The variability between animals was limited, with a mean of 0.61 ± 0.07 AAV genomes per haploid genome. To obtain a more detailed picture, clusters of GSTp-positive and GSTp-negative cells were dissected from paraffin liver sections from six of the rats, and genomic DNA was extracted. Quantification by PCR on these samples demonstrated comparable viral genome copy numbers in preneoplastic vs normal hepatocytes for each rat (Figure 4e) .
As viral genome integration events are not always accompanied by transgene expression, 3 0 -linear amplification-mediated (LAM)-PCR was performed on total genomic DNA samples from the liver of scAAV-GFP-injected rats, in order to determine vector ISs within the rat genome. scAAV integration was detected in 9 out of 10 rats (Table 1 ). In total, only 79 IS were detected, 63 exact mappable and 16 multiple mappable IS. Between 1 and 16 ISs were detected per animal. For the exact mappable IS, 46.0% were located upstream, 25.4% were located in and 28.6% were located downstream of the next RefSeq gene, whereas no integration hotspots were observed. Further analysis demonstrated that there was a high frequency of concatemers, which are assumed to be mostly episomal, in each animal (up to 100%; Figure 5a ). Figure 5b presents the ingenuity pathway analysis for the genes located next to the IS with a relative sequence count of 410%. An IS found with a high relative sequence count can reflect a higher proliferation capacity of the cells containing the integrated rAAV genome. The genes identified are involved in various cellular functions, and we evaluated the possibility of rAAV IS at or near cancer-related genes using the Tumour Gene Database (TGBD). None of the ISs were close to Abbreviations: AAV, adeno-associated virus; GFP, green fluorescent protein; LAM, linear amplification mediated; rAAV, recombinant AAV; scAAV, selfcomplementary AAV. LAM-PCR was used to analyse rAAV integration in 1 mg of total DNA derived from liver samples of scAAV-GFP-injected rats. In total, 418 000 454 reads were characterized, which revealed 79 integration sites.
scAAV transduction of newborn rat liver V Gauttier et al known oncogenes and none seem to cause any severe side effects. 3 0 -LAM-PCR was also performed on genomic DNA prepared from GSTp-positive and GSTp-negative clusters of cells dissected from liver sections of six rats. However, no genomic IS could be identified despite several attempts, indicating that rAAV vector integration occurred at a very low frequency.
These results in newborn rats are in alignment with a previous report, which concluded a low frequency of rAAV2 vector integration after liver-directed gene transfer in adult mice.
14 In this work, the IS analysis did not reveal any correlation between tumour initiation and rAAV insertion. They also confirm a recently published study, which showed that injection of therapeutic AAV2/8 vector to glucose-6-phosphatase-anull (G6pc À / À ) mice, as young as 2 weeks old, corrected their metabolic disorder, and that these mice thereafter developed normally for 70-90 weeks without any hepatic abnormalities. 15 In contrast to previous studies showing rAAV delivery to the newborn can result in liver tumours, 7, 8 no evidence of such tumourigenesis was detected in this study. Although we have no explanation for this discrepancy, it is noteworthy that we used a different species (rat vs mouse). To our knowledge, liver tumours related to rAAV transduction have only ever been reported in mice, never in any other species. Furthermore, our integration study did not reveal any specific hotspot of integration in the genome. The strength of this model resides in the use of a very widely known and sensitive model of liver carcinogenesis. In this context, the absence of any indication of an increase in preneoplastic lesions is valuable and supports the safety of rAAV in the clinic for liver-directed gene therapy in the adult, and also in the perinatal period. 16, 17 
MATERIALS AND METHODS

AAV plasmid and vector production
The vector plasmid used in this study was based on the pHpa-trsSK vector, 18 encoding GFP under the control of the CMV promoter. A stretch of four copies of the miR142 target sequence was added downstream of the GFP complementary DNA as described, 19 to avoid an induction of the immune response. The recombinant scAAV2/8 vector was produced and titered by the Vector Core Facilities of Nantes Hospital, as previously described. 20 
Animal experiments
Pregnant Wistar females were purchased from Janvier Laboratory (Le Genest St-Isle, France), and were kept in the Nantes IFR26 animal facility. Animal housing and surgical procedures were conducted according to the guidelines of the French Agriculture Ministry and were approved by the local ethical committee. Newborn rats were injected with AAV-GFP or PBS in the temporal vein at a dose of 5.10 12 vg kg À 1 . In the positive carcinogenesis group, 6-week-old male rats received an intraperitoneal injection of DEN (Sigma, St Louis, MO, USA) at 200 mg kg À 1 . At 6 weeks, the rats were put on a diet containing 0.02% 2-AAF for a period of 8 weeks. The animals were killed at 14 weeks.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed/paraffinembedded successive liver sections (5 mm) essentially as previously described. 21 Twelve sections, obtained from four different paraffin blocks, were analysed for each rat. Sections were deparaffinized and endogenous peroxidase activity was inhibited for 30 min by incubation in a 3% H 2 O 2 solution in PBS. Monoclonal primary antibody (anti-GFP 1/100, Clontech (Mountain Veiw, CA, USA), and anti-GSTp 1/1000 from Assaydesigns, Ann Arbor, MI, USA) diluted in PBS containing bovine serum albumin (1% w/v) and Tween 20 (0.1% v/v) was applied at room temperature. GSTp and GFP-expressing cells were revealed with biotinylated-secondary antibody and streptavidin-peroxidase using diaminobenzidine as a chromogenic substrate. Slides were counterstained with hematoxylin and the GFP and GSTp-positive clone numbers were calculated per cm 2 of liver section. A mean surface of 16.11 ± 1.26 cm 2 was screened for each animal. The GFP-positive cell index was calculated as the percentage of positively stained cells in 10 fields at Â 40 magnification (that is, at least 3000 cells).
To monitor the GSTp-positive surface, after immunohistochemical staining for GSTp, images of liver sections at Â 40 magnification were analysed with ImageJ software (NIH, Bethesda, MD, USA). The pictures were processed with colour deconvolution software to discriminate the diaminobenzidine (brown) from the hematoxylin (purple) staining. The percentage of brown area on the picture corresponding to the GSTppositive surface was calculated by ImageJ software.
Quantification of AAV vector genomes
Total cellular DNA was extracted from liver tissue with a standard phenol/ chloroform method. Detection and quantification of vector genomes in extracted DNA were performed by quantitative PCR on 200 ng of DNA. The values were normalized with the rat b-actin gene. A standard curve was generated using dilutions of AAV vector plasmid in genomic DNA extracted from rat liver. GFP-forward, 5
0 -ACTACAACAGCCACAACGTCTAT ATCA-3 0 ; GFP-reverse, 5 0 -GGCGGATCTTGAAGTTCACC-3 0 ; rat b-actin-forward, 5 0 -AGCCATGTACGTAGCCATCCA-3 0 ; rat b-actin-reverse, 5 0 -TCTCCGGA GTCCATCACAATG-3 0 .
LAM-PCR for the detection of rAAV proviruses
LAM-PCR analysis was performed on DNA extracted from liver samples as previously described. 22 The initial preamplification reaction (linear amplification) was carried out with 1 mg of genomic DNA using biotinylated primers (AAV-CMV-1, 5 0 -GCATCGCATTGTCTGAGTAGG-3 0 ), which anneals at the 3 0 -end of the rAAV vector, and immobilized on paramagnetic streptavidin beads. Double-stranded DNA cleavage with Tsp509I or MseI and linker ligation was performed in the semisolid streptavidin phase followed by denaturation of unbiotinylated singlestranded DNA as a template for a nested PCR reaction. First exponential PCR was performed using vector-specific (AAV-CMV-2, 5 0 -GTAGGTGTCATTC TATTCTGGG-3 0 ) and linker-specific (LCI, 5 0 -GACCCGGGAGATCTGAATTC-3 0 ) primers. PCR-amplicons were again immobilized on paramagnetic strepatvidin beads, washed and denatured. Second exponential PCR was performed by nested vector-specific (AAV-CMV-3, 5
0 -GACAGCAAGGGGGAG GATTG-3 0 ) and linker-specific (LCII, 5 0 -GATCTGAATTCAGTGGCACAG-3 0 ) primers. Preparation for GS FLX Titanium 454 pyrosequencing scAAV transduction of newborn rat liver V Gauttier et al implemented by Roche (Mannheim, Germany) was performed as previously described, 23 whereas DNA barcoding was used to allow parallel sequencing of multiple samples in a single sequencing run. Vector-genome junctions were identified by alignment of sequences to the rat genome (assembly November 2004) using the UCSC BLAT genome browser (http://genome.ucsc.edu/) and characterized as previously described. 23, 24 In parallel, concatemeric rearrangements were detected and analysed as recently published. 25 
Statistics
Statistical comparisons between experimental groups were performed by one-way analysis of variance test. A Po0.05 value was considered to be statistically significant.
